The landscape of preclinical drug discovery is undergoing a profound metamorphosis. For decades, the standard for toxicology and safety assessment was a linear, one-way process: animals were treated, tissues were harvested, slides were examined by a pathologist, and the resulting glass slides were relegated to long-term storage, effectively becoming "dark data."
However, the intersection of digital pathology, artificial intelligence, and evolving regulatory mandates is transforming these archives into a goldmine. By applying advanced computational analysis to legacy samples, researchers are finding ways to extract deeper biological insights without the need for additional animal testing. This shift not only accelerates drug development but aligns with the global imperative to refine, reduce, and replace animal models in scientific research.
The Evolution of the Digital Slide
The rise of digital pathology was accelerated by necessity during the COVID-19 pandemic. When physical access to laboratories and microscopes became restricted, the digitizing of slides allowed pathologists to maintain continuity of operations through remote analysis. What began as a logistical workaround, however, quickly evolved into a technological revelation.
"Before, the pathology endpoint was just a report," explains Dr. Aleksandra Zuraw, a veterinary pathologist at Charles River Laboratories. "Now, you have the digitized slide, which is pixels. And pixels are data."
Once a slide is digitized, it ceases to be a static image. It becomes a multidimensional data source that can be processed by machine learning algorithms to identify subtle patterns—molecular shifts, architectural changes, and cellular responses—that the human eye might overlook. This transition from "analog observation" to "computational analysis" allows scientists to pose entirely new questions to samples that were collected years or even decades ago.
Chronology of a Regulatory Shift
The move away from traditional animal-heavy testing is not merely a scientific trend; it is a policy-driven mandate. The timeline of this transition reflects a concerted effort by global regulators to modernize preclinical safety standards.
- 2022: The FDA Modernization Act 2.0: A landmark piece of legislation that signaled a fundamental shift in the U.S. approach to drug discovery. It provided the legal framework for regulators to accept non-animal methods (NAMs) in support of human trial applications, breaking the long-standing requirement for animal-only data.
- April 2024: Charles River Laboratories, a global leader in preclinical research, launched its "Alternative Methods Advancement Project." This initiative prioritized the development of technologies that extract more value from existing studies, including the use of virtual control groups.
- April 2025: The FDA published a comprehensive roadmap for reducing animal testing in preclinical safety studies. The roadmap began with specific focus areas, such as monoclonal antibodies, with a clear trajectory to expand to biologics and, eventually, new chemical entities.
- 2025–2026: The OECD issued new guidance on the use of "omics" analysis for preserved tissue, emphasizing the importance of standardized storage protocols to ensure that archived samples remain viable for molecular investigation.
- September 2026: The FDA released updated regulations further clarifying the path toward adopting NAMs, aiming to make animal studies the exception rather than the standard within the next three to five years.
Virtual Control Groups: The Arithmetic of Replacement
One of the most immediate impacts of this digitization is the implementation of "virtual control groups." In standard toxicology studies, researchers typically include a large number of "control" animals—animals that do not receive the test drug—to establish a baseline for comparison.
"Control animals are always a big fraction of every study," Dr. Zuraw notes. By leveraging vast, historical databases of digitized pathology and molecular data, researchers can now create "virtual" baselines. If a sufficiently robust historical dataset exists that mirrors the conditions of a new study, the number of control animals can be significantly reduced.
This is not a matter of simply "guessing" the baseline; it requires high-fidelity, matched data. Charles River’s current initiative focuses on curating these historical datasets to ensure that they are statistically comparable to new studies. By replacing physical control animals with data-driven virtual controls, researchers can cut animal usage through simple, rigorous arithmetic.
Mining the "FFPE" Archives
The heart of this new methodology lies in the formalin-fixed, paraffin-embedded (FFPE) blocks that have sat in archives for years. These blocks are time capsules of biological response.
Traditionally, if a researcher realized at the end of a study that they needed more information—such as a gene expression analysis or protein profiling—they were often forced to initiate a new, costly, and ethically burdensome animal experiment. Today, thanks to improved molecular extraction techniques and regulatory acceptance, these FFPE blocks can be re-analyzed.
"Now you have the option to use FFPE material that was already part of a lot of studies for additional information," says Dr. Zuraw. "You don’t lose the context of the study." Because the molecular findings can be cross-referenced with the original dosing information and the original pathology reports, scientists can achieve a "360-degree view" of a drug’s impact on an organism without subjecting a single additional animal to a trial.
Technological Frontiers: Virtual Staining
Beyond re-analyzing existing samples, the field is moving toward "virtual staining." This technology allows for the digital generation of tissue characteristics that would normally require chemical stains.
In a typical workflow, a tissue section is scanned in an unstained state, and software is then used to generate a digital representation of what that tissue would look like if it were stained for specific biomarkers. This process effectively skips the physical staining process, reducing the use of chemicals and the need for physical glass slides.
While this technology is still in its adoption phase, its implications are massive. By removing the physical barriers to analysis, labs can process more data with higher throughput. Dr. Zuraw views this as a potential "snowball effect." As the utility of digital images becomes undeniable, labs will be incentivized to invest in the infrastructure needed to create and share them, further democratizing access to high-quality biological data.
Implications for Future Drug Development
The shift toward digital pathology and the mining of archived tissue represents more than just a technological upgrade; it is a fundamental shift in the ethical and scientific framework of drug discovery.
1. Ethical Stewardship
The most immediate implication is the reduction of animal life used in research. As the FDA and other global regulators push for NAMs as the default, the industry is transitioning from a model of "experimental redundancy" to one of "data optimization."
2. Economic Efficiency
Running a preclinical study is immensely expensive. By reducing the number of animals required and minimizing the need for repeat experiments when questions arise, pharmaceutical companies can lower the barrier to entry for innovative drug candidates.
3. Scientific Precision
Digital analysis allows for a level of consistency that is difficult to achieve manually. AI-driven models can identify patterns across thousands of slides that a human pathologist might miss due to cognitive fatigue or natural subjectivity. This results in cleaner, more reproducible data.
4. Regulatory Resilience
Companies that invest in these new methodologies are better positioned to meet the increasingly stringent requirements of global regulators. The FDA’s stated goal of making animal studies the exception rather than the norm means that early adopters of these digital and computational techniques will likely face fewer hurdles during the drug approval process.
Conclusion: The Path Forward
Turning these advanced methodologies into routine practice will require a culture of collaboration. "You still need enough early adopters to generate precedent," Dr. Zuraw concludes. As these pioneers troubleshoot the challenges of integrating digital pathology into standard safety assessments, they create a blueprint for the rest of the industry to follow.
The era of "mining" existing tissue is no longer a futuristic concept—it is a current necessity. By viewing every digitized slide and every archived tissue block not as a finished report, but as a dynamic data source, the scientific community is building a more efficient, ethical, and predictive path toward the medicines of the future. The "snowball effect" has begun, and the standard of care for animal research is changing for the better.
About the Author
